Martin C. Woodle, Ph.D.
Chief Executive and Scientific Officer, Co-Founder
Dr. Woodle has over 20 years of experience in drug delivery and therapeutic drug development, including leading the research department at Liposome Technology, Inc. (marketed by J&J) that developed PEGylated Stealth® liposomes for Doxil®, marketed by J&J, leading toxicology and formulation development at Genta that supported initiation of Genasense clinical development, and leading the Synthetic Gene Vector department within Novartis he spun off to form Intradigm Corp., which developed the first nanoparticle siRNA formulation showing preclinical efficacy.
Puthupparampil Scaria, Ph.D.
Vice President of Research & Development, Co-founder
Dr. Scaria has over 20 years of research experience with nucleic acids and Nanoparticle delivery technology for nucleic acids. After post-doctoral training at University of California, San Francisco, Dr. Scaria joined Novartis’ Genetic Therapy Inc. to lead the development of tissue targeted delivery systems for nucleic acids. At Novartis, he developed a ligand targeted Nanoparticle for tumor targeted delivery of DNA, a breakthrough in nucleic acid delivery at the time. Dr. Scaria was a co-founder and Vice President of Intradigm Corporation where he led the development of neo-vasculature targeted Nanoparticles and their adaptation for siRNA for anti-angiogenic therapeutics. His team was the first to demonstrate in vivo tumor efficacy using siRNA, delivered by tissue targeted Nanoparticle. Dr. Scaria co-founded Aparna Biosciences Corporation with Dr. Martin Woodle, to develop Nanoparticle based therapeutics for cancer and other critical diseases. Dr. Scaria has more than 30 scientific publications and several pending patent applications.
Yijia Liu, Ph.D.
Director of Biology
Previously, Dr. Liu served as a Principal Scientist at Intradigm Corporation, working on RNAi drug discovery and preclinical research on RNAi therapeutics for cancer. Dr. Liu has many years of extensive research experience in cell biology and in vivo studies of siRNA and nucleic acid nanoparticles. Dr. Liu received her medical degree from Suzhou Medical University, China and was awarded her Ph.D. degree in Medical Cell Biology from Uppsala University, Sweden. She had her postdoctoral training at Department of Molecular Medicine, Cornell University. Dr. Liu has many peer-reviewed publications and is inventor on a number of patent applications.